Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
- Conditions
- Locally Advanced Rectal AdenocarcinomaStage IVA Rectal Cancer AJCC v7Stage IIIA Rectal Cancer AJCC v7Stage IIIB Rectal Cancer AJCC v7Stage IV Rectal Cancer AJCC v7Stage IVB Rectal Cancer AJCC v7Metastatic Rectal AdenocarcinomaRectal AdenocarcinomaStage III Rectal Cancer AJCC v7Stage IIIC Rectal Cancer AJCC v7
- Interventions
- Drug: CapecitabineDrug: FluorouracilDrug: LeucovorinDrug: OxaliplatinRadiation: Radiation TherapyBiological: Talimogene Laherparepvec
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT03300544
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Dorte Nielsen
- Target Recruit Count
- 39
- Registration Number
- NCT03295084
- Locations
- 🇩🇰
Herlev Hospital, Herlev, Denmark
NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer
- Conditions
- Colorectal NeoplasmColorectal CancerRectal NeoplasmsChemotherapy EffectIntestinal DiseaseIntestinal NeoplasmsRectal Cancer
- Interventions
- Drug: FOLFOX regimen (oxaliplatin/leucovorin/5FU)Drug: CapecitabineDrug: CAPOX (oxaliplatin/capecitabine)
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 124
- Registration Number
- NCT03280407
- Locations
- 🇩🇰
Vejle Hospital, Vejle, Denmark
Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
- Conditions
- Stage II Gastric Cancer AJCC v7Stage IIIA Gastric Cancer AJCC v7Stage IIIB Gastric Cancer AJCC v7Epstein-Barr Virus PositiveGastric AdenocarcinomaMismatch Repair Protein DeficiencyStage IIA Gastric Cancer AJCC v7Stage IB Gastric Cancer AJCC v7Stage IIB Gastric Cancer AJCC v7Stage III Gastric Cancer AJCC v7
- Interventions
- Drug: CapecitabineOther: Laboratory Biomarker AnalysisBiological: PembrolizumabRadiation: Radiation Therapy
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 40
- Registration Number
- NCT03257163
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- ASLAN Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT03231176
- Locations
- 🇨🇳
No.81 Hospital of The Chinese People's Liberation Army, Nanjing, China
🇨🇳There is 22 sites located in other cities of China, including Nanjing, Nanjing, China
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
- Conditions
- Gastric CancerGastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1007
- Registration Number
- NCT03221426
- Locations
- 🇺🇸
Fox Chase Cancer Center ( Site 0006), Philadelphia, Pennsylvania, United States
🇨🇦Cross Cancer Institute ( Site 0033), Edmonton, Alberta, Canada
🇨🇦Jewish General Hospital ( Site 0034), Montreal, Quebec, Canada
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- Conditions
- Glioma of BrainBrain Tumor AdultCancerBrain CancerGlioblastomaBrain TumorGlioblastoma Multiforme (GBM)Glioblastoma, AdultBrain Tumor, Primary
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 67
- Registration Number
- NCT03213002
- Locations
- 🇺🇸
Lenox Hill Brain Tumor Center, New York, New York, United States
Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT03204734
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
- Conditions
- Urothelial Carcinoma
- Interventions
- Biological: avelumabBiological: bevacizumabDrug: capecitabineDrug: cisplatinDrug: cyclophosphamideDrug: 5Fluorouracil (5-FU)Drug: fulvestrantDrug: leucovorinDrug: nab-paclitaxelDrug: LovazaRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03197571
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
- Conditions
- Ovarian Cancer
- Interventions
- Biological: AvelumabBiological: BevacizumabDrug: CapecitabineDrug: CyclophosphamideDrug: 5-fluorouracilDrug: FulvestrantDrug: LeucovorinDrug: PaclitaxelDrug: omega-3 acid ethyl estersDrug: OxaliplatinRadiation: Stereotactic Body Radiation TherapyBiological: ALT-803Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6301Biological: haNK®
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03197584
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.